ID   KMS-11/BTZ
AC   CVCL_4V71
SY   KMS11/BTZ
DR   JCRB; JCRB1642
DR   Wikidata; Q54900165
RX   PubMed=20555361;
CC   Characteristics: Produces IgG kappa.
CC   Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade).
CC   Sequence variation: FGFR3 p.Tyr373Cys (c.1118A>G) (from parent cell line).
CC   Sequence variation: Homozygous for TRAF3 p.Lys191Leufs*3 (from parent cell line).
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 12
ST   D16S539: 9,13
ST   D5S818: 10,12
ST   D7S820: 11,12
ST   TH01: 6,9
ST   TPOX: 12
ST   vWA: 17,18
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_2989 ! KMS-11
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 12-03-20; Version: 6
//
RX   PubMed=20555361; DOI=10.1038/leu.2010.137;
RA   Ri M., Iida S., Nakashima T., Miyazaki H., Mori F., Ito A.,
RA   Inagaki A., Kusumoto S., Ishida T., Komatsu H., Shiotsu Y., Ueda R.;
RT   "Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in
RT   preventing the accumulation of unfolded proteins and fatal ER
RT   stress.";
RL   Leukemia 24:1506-1512(2010).
//